Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 16 weeks reduced ...

With patient enrollment now complete, topline results are expected early next year from a Phase 3 trial testing PAH treatment ...

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations in COPD, ILD, and pulmonary hypertension.

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 ...

Merck delivered a home run with its Phase 3 HYPERION trial, showcasing WINREVAIR’s prowess in battling pulmonary arterial ...

The projection represents a negative annual growth rate of 0.08%. The total number of diagnosed prevalent cases of pulmonary ...

Step counters and smartwatches may help your heart, but theres a catch. While Johns Hopkins hails their benefits, a deeper ...

A comprehensive new study from the Centers for Disease Control and Prevention’s National Center for Health Statistics shows that chronic health conditions are nearly universal among Americans age 85 ...

Topline results were announced from a phase 3 study evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension (PAH).

Merck's Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study ...